Topical immunomodulatory agents and their targets in inflammatory skin diseases (Q34264187)

1 August 2017

1 reference

title

Topical immunomodulatory agents and their targets in inflammatory skin diseases (English)

1 reference

1 August 2017

Wollenberg A

1

1 reference

1 August 2017

Bieber T

series ordinal

2

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Transplantation Proceedings

1 August 2017

published in

1 reference

1 August 2017

volume

33

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

2212-2216

1 reference

Short-term use of cyclosporin A in severe psoriasis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

FK506 in the treatment of inflammatory skin disease: promises and perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

[Immunosuppressive macrolides and their use in dermatology]

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506).

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Anti-inflammatory effect of FK-506 on human skin mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Tacrolimus ointment for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

[Successful topical administration of cyclosporin A in pyoderma gangraenosum]

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Topical tacrolimus for pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Erosive mucosal lichen planus: response to topical treatment with tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Inhibition of contact allergy reactions by topical FK506.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

Atopic dermatitis: from the genes to skin lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901944-3

7 January 2021

10.1016/S0041-1345(01)01944-3

Identifiers

DOI

1 reference

1 August 2017

1 reference